L-Theanine
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Non-proteinogenic amino acid (glutamate analogue) |
| Molecular Formula / CAS | C₇H₁₄N₂O₃ · CAS 3081-61-6 |
| Primary Botanical Source(s) | Green tea (Camellia sinensis) |
| Plant Part | Leaf |
| Typical Content | Roughly 1–2% of dried green tea leaf by weight, the most abundant free amino acid in tea |
| Solubility / Format | Water-soluble amino acid; available as a high-purity standardised isolate powder |
| Sourcing Status | Product-live — genuine match via Herbuno’s green tea extract line |
| Buy from Herbuno | L-Theanine 98% Powder (Green Tea) |
Name origin: L-theanine takes its name from thea, the historical botanical genus name for tea, reflecting its status as a compound essentially unique to Camellia sinensis among common dietary sources. Traditional use: Tea itself carries one of the longest continuous traditional-use histories of any plant in the HerbIQ index, consumed for millennia across Chinese and broader East Asian culture; L-theanine specifically was not isolated and identified until 1949, and its contribution to tea’s traditionally described “calm alertness” effect (distinguishing tea from coffee’s more purely stimulating reputation) has only been investigated scientifically in recent decades. Research trajectory: Early L-theanine research through the 1990s–2000s used electroencephalography to document its distinctive effect on brain alpha-wave activity associated with relaxed alertness; the 2010s and 2020s saw a substantial expansion of commercial interest and marketing, prompting recent systematic reviews and meta-analyses to critically re-examine whether the accumulated human clinical trial evidence actually supports the scale of the claims now made for L-theanine supplements. Commercial source: Green tea leaf is the standard commercial source of L-theanine, and Herbuno’s standardised extract reflects this well-established, genuine botanical match.
Evidence for L-Theanine Applications
L-theanine is structurally related to the neurotransmitter glutamate and is well absorbed from the intestine, readily crossing the blood-brain barrier. Early human EEG research found that L-theanine significantly increases activity in the brain’s alpha frequency band, an effect associated with relaxation without drowsiness, though this effect was originally demonstrated at doses higher than typically found in a single cup of tea, prompting follow-up research at more realistic dietary intake levels (Higashiyama et al. 2011). Claim strength: Moderate.
A 2025 systematic review and meta-analysis of randomised, placebo-controlled clinical trials evaluating L-theanine’s effect on cognitive function concluded the evidence is “promising, but not completely conclusive,” finding some support for improved attention and reaction time measures, particularly when combined with caffeine, while noting inconsistency across individual trial results and calling for more rigorously standardised future research (et al. 2025). Claim strength: Moderate.
A separate and notably more cautious 2025 review examined the full breadth of L-theanine research directly and concluded that, despite widespread marketing claims around relaxation, stress reduction, sleep quality and cognitive enhancement, the supporting evidence remains limited and the science does not yet match the scale of commercial hype behind L-theanine as a trending supplement, explicitly urging caution around pharmacologic-dose use in the wider population pending better clinical trial data (et al. 2025). This represents an important, deliberately balanced counterpoint to more promotional framing of L-theanine research. Claim strength: Moderate (with explicit caution).
A large, very recent meta-analysis of 31 randomised controlled trials (n = 1,168) comparing oral L-theanine against placebo found that a single 200 mg dose taken 30–60 minutes before cognitive testing significantly improved choice reaction time, indicating a genuine acute attention benefit at this specific, well-defined dose and timing, while other secondary outcomes (repeated-dose stress, anxiety, depressive symptoms) showed more mixed results across the pooled trials. Claim strength: Moderate.
Taken together, the most defensible summary of the L-theanine evidence base is that acute, single-dose effects on relaxation-associated brain activity and attention are reasonably well documented, while claims around sustained stress reduction, sleep quality improvement and broader cognitive enhancement rest on a more inconsistent and still-developing body of human trial evidence. Formulators should calibrate marketing claims to this more measured picture rather than the broader wellness-supplement framing common in the consumer market. Claim strength: Moderate.
Dosage & Formulator Specification
The clinical trial literature most consistently demonstrating an acute cognitive/attention benefit has used single doses around 200 mg, taken 30–60 minutes before the outcome measure; EEG relaxation research has used somewhat variable dose ranges, and repeated-dose trials for sleep or sustained stress outcomes have shown less consistent results across the available literature.
Analytical quantification of L-theanine is performed by HPLC, the standard method for green tea amino-acid profiling; formulators should request L-theanine-specific chromatographic data given that green tea also contains numerous other free amino acids and catechins that a generic “amino acid” or “green tea extract” specification would not distinguish.
Given the documented inconsistency in the human trial literature for repeated-dose and longer-duration outcomes specifically, formulators should be conservative and specific in marketing claims, distinguishing well-supported acute attention effects from the less consistently demonstrated stress-reduction and sleep-quality claims common in commercial L-theanine marketing.
Regulatory positioning for L-theanine follows established green-tea-derived-ingredient precedent in most markets, given tea’s extremely long dietary use history and L-theanine’s generally favourable toxicology profile in available safety studies; no L-theanine-specific regulatory dosing limit exists, though formulators should still exercise the general caution recommended by recent critical reviews regarding pharmacologic-dose use pending stronger clinical substantiation.
Frequently Asked Questions — L-Theanine
The evidence is more mixed than typical marketing suggests. A 2025 review concluded that while some effects on relaxation-associated brain activity and acute attention are reasonably well documented, the broader evidence for many popular claims (stress reduction, sleep quality, general cognitive enhancement) remains limited, and the science does not yet fully match the hype.
A large recent meta-analysis of 31 randomised trials found that a single 200 mg dose taken 30–60 minutes before cognitive testing significantly improved reaction time, representing one of the more clearly demonstrated acute effects in the current research literature.
Research suggests L-theanine combined with caffeine may improve cognitive performance, alertness and focus more consistently than either compound alone, which is the rationale behind this common commercial pairing, though individual trial results still vary.
L-theanine is found abundantly and essentially uniquely in tea among common dietary sources, typically making up 1–2% of dried green tea leaf by weight. It was first isolated and identified as a distinct compound from tea in 1949.
Related compounds: Hypericin, 5-Hydroxytryptophan (5-HTP)